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Over the years, a chasm between biomedical researchers 
and the patients who may benefit from their discoveries has 
been opened. On one hand, millions of patients with diseas-
es such as cancer are anxiously waiting for new remedies to 
save their lives. On the other hand, many exciting basic 
science discoveries do not have opportunities to find practi-
cal applications. Recently emerging translational medicine 
aims to tie basic research to clinical results and optimize 
both patient care and preventive measures. 
1  Translational medicine is a people-oriented 
medical practice 
Translational medicine converts promising laboratory dis-
coveries into clinical applications and elucidates clinical 
questions with the use of benchwork, aiming to facilitate 
prediction, prevention, diagnosis, and treatment of diseases. 
It is regarded as a two-way road—bench to bedside and 
bedside to bench—and requires close collaboration between 
clinicians/public health professionals and basic scientists. 
With the ultimate goal to develop more effective preven-
tive/therapeutic approaches and improve clinical outcomes 
and health levels, translational medicine is therefore a peo-
ple (patients and the general population as a whole)-oriented 
medical practice. 
2  Challenges for China’s health care system 
The past three decades have witnessed tremendous advanc-
es in China in the development of living conditions, food 
and nutrition, and the health care system. However, while 
the economy grows and society rapidly transforms, the 
health care system faces multiple problems (Table 1). For 
example, rapid industrialization and urbanization may per-
turb ecology, pollute the environment, and even affect resi-
dents’ homes. In some regions, occupational, food, and drug 
safety should be strengthened and sanitary drinking water 
and toilet systems should be provided to the residents. 
China bears a complex disease spectrum (Table 2). On 
one hand, communicable diseases frequently seen in devel-
oping countries remain a heavy burden. For example, China 
has approximately 100 million and 4.5 million people in-
fected with the hepatitis B virus and tuberculosis, respec-
tively. Each year there are 800000 new cases of traditional 
sexually transmitted diseases, and there are an estimated 
700000 people living with human immunodeficiency virus. 
On the other hand, chronic diseases commonly found in 
developed countries are also the leading causes of death and 
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Table 1  Social transformation and related health problems in China 
Social transformation Consequence and major health problems 
Rapid industrialization Ecological degradation; environmental pollution; toxins; occupational hazards 
Rapid progress of market economy Problems in employment and social security; lifestyle and stress 
Rapid urbanization Problems in living conditions, housing, transportation; stress and social security 
Rapid globalization Cross-border disease transmission 
Aging population Chronic diseases; health care and social security for aged people 
Change of lifestyle Disease and death associated with unhealthy lifestyle 
Table 2  Major diseases in China 
Major communicable disease Major chronic disease 
Infectious disease Accounts for 12% of deaths Chronic disease 
Leads to shortening of life span by 
49%. 
Hepatitis B 
More than 100 million people are infected with 
the hepatitis B virus, and 300000 people die of 
hepatitis B virus-related diseases every year. 
Cancer 
Cancer accounts for some 1890000 
deaths each year. 
Tuberculosis 
China has 4.5 million tuberculosis cases annually; 
160000 people succumbed to this disease in
2008. 
Heart disease 
Each year approximately 
1250000 people die of heart disease. 
Traditional sex transmitted disease Each year there are 800000 new cases in China. Stroke 
Cerebral stroke causes 1900000 
deaths each year. 
Acquired immunodeficiency syn-
drome (AIDS) 
More than 700000 cases living with HIV/AIDS Hypertension 
There are 200 million patients with 
hypertension in China. 
Emerging infectious diseases Swine flu (H1N1), avian flu Diabetes mellitus 
There are 90 million patients with 
diabetes in China. 
 
disability in China. For example, cancer and cardiovascular 
disease represent the two leading causes of death, and hy-
pertension and diabetes mellitus are diagnosed in some 200 
million and 90 million people annually in China, respec-
tively. These data demonstrate that the health care system in 
China is facing great challenges, and a state effort is needed 
to meet these challenges. 
3  Principles for development of translational 
medicine in China 
China is deepening its reform to improve its people’s wel-
fare. The development of translational medicine will accel-
erate disease control and finding solutions for health prob-
lems, with the following principles being emphasized. 
3.1  Close collaboration 
Translational medicine is a multidisciplinary program that 
integrates research from the medical sciences, basic scienc-
es, and social sciences, with the aim of optimizing patient 
care and preventive measures that may extend beyond 
health care services. Pharmaceutical or biotech companies 
that use a patient-driven approach to drug development also 
play an important role in translational medicine. Therefore, 
close collaboration among clinical practitioners, basic re-
searchers, biotechnologists, ethicists, sociologists, and oth-
ers is essential to the development of translational medicine. 
Moreover, translational medicine is a medical practice 
based on interventional epidemiology. Policy-makers and 
those in government may facilitate the practice not only by 
funding support, but also by organizing social resources and 
evidence-based policy-making and transforming discoveries 
in translational research into public health services and pre-
ventive approaches. 
3.2  Etiology and prevention of disease 
Environmental factors are responsible for diseases from 
infections to immunologic diseases and cancer. Therefore, 
translational research should identify specific environmental 
factors that cause health problems, develop methods to 
eliminate these factors, and investigate preventive strategies 
to decrease potential harm to residents. Furthermore, path-
ogenesis of environmental health problems should be eluci-
dated using genomic, proteomic, and other systematic tech-
nologies. These approaches are important, especially for 
regional disease caused by environmental factors. These 
efforts may facilitate science- and evidence-based poli-
cy-making and will in turn greatly reduce disease burden 
and improve people’s welfare. 
3.3  Identification of biomarkers for early diagnosis 
Identification of biomarkers for early diagnosis of diseases 
such as cancer remains an urgent need to improve the clini-
cal outcome of patients. Advances in genomics, proteomics, 
epigenomics, and molecular pathology will provide many 
candidate biomarkers with potential clinical value. 
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3.4  Translating science and technology into grass-
roots health care 
China remains a developing country whose disease burden 
is huge, while a large proportion of its residents are unable 
to afford their prescription drugs because of abject poverty. 
The level of reimbursement from medical insurance is very 
limited, especially for diseases such as cancer, although 
more than 1.27 billion people have been covered by rural 
and urban medical insurance to date. Hence, reliable and 
cost-effective biotechnologies/bioremediations should be 
encouraged in translational research. A paradigm for this is 
the treatment of acute promyelocytic leukemia, which was 
considered to be the most fatal type of leukemia five dec-
ades ago. The application of all-trans retinoic acid and arse-
nic trioxide attains a high complete remission rate, while 
combination of the two plus chemotherapy achieves a 
five-year overall survival of >90% for all patients, making 
acute promyelocytic leukemia a curable disease. Interest-
ingly, according to the statistics from the Shanghai Institute 
of Hematology, Ruijin Hospital, the overall cost of using 
this combinatory regimen is generally within CNY (RMB) 
100000, while allogeneic transplantation, which only ob-
tains a five-year survival rate of 60%70%, costs CNY 
300000400000. Another example comes from Shanghai 
Children’s Medical Center in treating acute lymphoid leu-
kemia, which accounts for 80% of childhood leukemia. This 
center establishes a standard childhood acute lymphoid 
leukemia treatment protocol in which patients receive pred-
nisone, vincristine, daunorubicin, cyclophosphamide, cy- 
tarabine, dexamethasone, and L-asparaginase according to 
their risk stratification. Intriguingly, overall continuous 
complete remission reaches 80%, while total costs per pa-
tient are under CNY 80000. At present, quality treatment 
services for these two categories of leukemia among chil-
dren in all rural areas of China are covered by the New Ru-
ral Cooperative Medicare Scheme, with a reimbursement 
rate of 90%. These two examples demonstrate that innova-
tion and cost-effectiveness could be fulfilled and that the 
best practices in clinical study should be transformed into 
policy-making in translational medicine. 
4  Concluding remarks 
The Chinese government strives to protect and promote 
citizens’ health and improve their welfare. In 2009, China 
launched long-awaited health reforms with an investment 
plan of CNY 850 billion (USD 124 billion) for the first 
three years (2009–2011) to improve the medical and health 
care system to achieve universal access to basic medical and 
health services for all of its citizens. Moreover, the 12th 
Five-year Socio-economic Development Plan (2011–2015) 
has been launched, which includes as part of the core indi-
cator health-related objectives such as the increase of one 
year of life expectancy. Translational medicine, a multidis-
ciplinary practice, should help to cultivate health system 
innovation and health industry growth and facilitate the 
construction of a harmonious society. 
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